Date: 2015-10-29
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Sanofi (France)
Product: SAR438335
Action
mechanism: GLP-1R/GIPR dual agonist/glucagon-like peptide 1 (GLP-1) - Gastric inhibitory polypeptide receptor (GIPR) dual agonist
Disease: diabetes
Therapeutic area: Metabolic diseases
Country:
Trial details:
Latest
news: * On October 29, 2015, Sanofi announced that a GLP-1R/GIPR dual agonist, SAR438335, entered Phase I in diabetes. Sanofi now has two dual agonists in Phase I in diabetes, a GLP1/GIPR and a GLP1-GCGR agonists, SAR438335 and SAR425899.
